MaaT Pharma Logo

MaaT Pharma

A clinical-stage biotech developing microbiome-based therapeutics for oncology.

MAAT | PA

Overview

Corporate Details

ISIN(s):
FR0012634822 (+1 more)
LEI:
969500CQQB6XUNW6CN97
Country:
France
Address:
70 AVENUE TONY GARNIER, 69007 LYON

Description

MaaT Pharma is a clinical-stage biotechnology company specializing in the development of microbiome-based therapeutics. The company's primary focus is on oncology, aiming to improve survival outcomes for cancer patients by modulating the immune system through the gut microbiome. It develops Microbiome Ecosystem Therapies (MET) designed to restore gut microbiome symbiosis. The company's pipeline includes product candidates for treating complications in patients with blood cancers and solid tumors, with its lead candidate, MaaT013, in late-stage development for acute Graft-versus-Host Disease (aGvHD). MaaT Pharma utilizes an AI-powered platform for drug development and has its own cGMP manufacturing capabilities.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-15 10:41
Franchissement de seuils
French 108.0 KB
2025-12-08 18:00
Inside Information / Other news releases
English 139.6 KB
2025-12-08 18:00
Informations privilégiées / Autres communiqués
French 145.6 KB
2025-11-21 11:22
Franchissement de seuils
French 107.2 KB
2025-11-14 23:05
Inside Information / Operations of the issuer (acquisitions, sales...)
English 121.9 KB
2025-11-14 23:05
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
French 176.1 KB
2025-11-13 19:40
Inside Information / Other news releases
English 193.4 KB
2025-11-13 19:40
Informations privilégiées / Autres communiqués
French 156.5 KB
2025-11-05 07:30
Inside Information / Other news releases
English 162.7 KB
2025-11-05 07:30
Informations privilégiées / Autres communiqués
French 132.6 KB
2025-11-04 07:30
Inside Information / News release on accounts, results
English 109.1 KB
2025-11-04 07:30
Informations privilégiées / Communiqué sur comptes, résultats
French 167.6 KB
2025-11-03 18:00
Inside Information / Other news releases
English 150.3 KB
2025-11-03 18:00
Informations privilégiées / Autres communiqués
French 163.0 KB
2025-10-13 14:47
Franchissement de seuils
French 106.3 KB

Automate Your Workflow. Get a real-time feed of all MaaT Pharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MaaT Pharma

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MaaT Pharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-07-12 N/A Other Sell 8 60.87 EUR
2024-07-11 N/A Other Sell 57 436.14 EUR
2023-12-22 N/A Other Buy 2,940 14,994.00 EUR
2023-12-22 N/A Other Buy 1,960 9,996.00 EUR
2023-09-27 N/A Other Buy 500 3,050.00 EUR

Peer Companies

Urteste S.A. Logo
Develops non-invasive urine tests for the early detection of multiple cancers.
Poland
URT
VALIRX PLC Logo
Life science company developing therapeutics for oncology and women's health.
United Kingdom
VAL
Vera Therapeutics, Inc. Logo
Clinical-stage biotech developing treatments for immunological and rare diseases.
United States of America
VERA
ViGenCell Inc. Logo
Develops immune cell therapies to treat cancer and other incurable diseases.
South Korea
308080
Viking Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapies for metabolic and endocrine disorders.
United States of America
VKTX
Vinext S.p.A. Logo
Develops sustainable technology for the oenology and agri-food sectors.
Italy
VNXT
Virax Biolabs Group Ltd Logo
Biotechnology company specializing in immune response detection and viral disease diagnosis.
United States of America
VRAX
Viridian Therapeutics, Inc.\DE Logo
Develops antibody-based therapies for serious and rare autoimmune diseases.
United States of America
VRDN
VivoSim Labs, INC. Logo
Develops 3D bioprinted human tissues for non-animal drug toxicology testing.
United States of America
VIVS
VOLITIONRX LTD Logo
Epigenetics company developing blood tests for early diagnosis of cancer and sepsis.
United States of America
VNRX

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.